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RESULTS: The MLHFQ showed similar metric proper-
ties across the studied countries; Cronbach’s alpha 
internal consistency was above the standard proposed 
for individual comparisons (0.9) for all countries. The
general lineal model showed that MLHFQ scores vary by
age, gender, and NYHA class (p < 0.001), that the inter-
action between scores and functional capacity was not
signiﬁcant (p = 0.363); only Australia and Italy’s scores
differed signiﬁcantly (p = 0.003). Adjusted means of
MLHFQ score were: 31 (95% CI 28.6–33.2), 44 (95%
CI 42.4–45.8), and 58 (95% CI 51.8–64.1); for class II,
III and IV respectively (class I sample was not enough to
deﬁne a reference score). CONCLUSIONS: These results
suggest that MLHFQ scores are comparable across 
countries (excepting Australia and Italy which will need
further research), allowing their use in international 
multicentric studies.
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While treatment guidelines recommend lowering choles-
terol to target levels, many remain above recommended
goal (LDL-C >= 100mg/dl). In a clinical trial, 72% of the
patients who received ezetimibe co-administered with
existing statin therapy reached NCEP II goal versus 19%
among patients who continued statin monotherapy.
OBJECTIVES: To assess cost-effectiveness of ezetimibe
10mg (EZ10) co-administration with simvastatin 10mg
(S10) versus a simvastatin dose titration strategy in
CHD/CHD equivalent patients (deﬁned in NCEP III
guidelines) who do not attain goal with S10 alone.
METHOD: A decision-analytic model was developed to
project lifetime costs and beneﬁts of lipid therapy. Clini-
cal trial data were used to estimate LDL-C reductions for
different treatment strategies. The effect of LDL-C reduc-
tions on CHD event rates was estimated using Framing-
ham equations and Spanish Instituto Nacional de
Estadística data on nonCHD-related mortality. Direct
costs of CHD events in Spain, Spanish prices for generic
simvastatin and EZ 10 price (based on German EZ10
price) were used to project lifetime costs. The model was
run for a population consisting of all patients in an obser-
vational lipid lowering treatment study in Spain who
started treatment with S10 and had not reached goal at
the ﬁrst LDL-C measurement after 60 days of treatment.
RESULTS: For these patients (mean age 62 years, 32%
male, 36% CHD & 64% CHD equivalent patients, base-
line LDL-C 148mg/dl), EZ10 co-administered with S10
compared to simvastatin titration is projected to increase
life expectancy by 0.23 years with a C/LY of €20,178.
The incremental cost per additional patient to goal in the
ﬁrst year was €1748 per year. CONCLUSION: Based on
the model, treatment with EZ10 co-administered with
S10 for patients not at goal is a cost-effective alternative
to statin titration, well under the limit C/LY of €30,000
considered acceptable in Spain.
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OBJECTIVES: 1) Compare the patients health perceived
between diagnosed of COPD, arterial hypertension
(HTA) and diabetes mellitus (DM) in Primary Care; and
2) to analyze the sociodemographics features associate 
to the quality of life (QOL) in these chronic pathologies.
METHOD: Cross-sectional descriptive study, from
2000–2002. We selected a random systematic sample:
624 hypertension ones, 148 HTA + DM and 278 COPD.
Dependent variable: Each patient fulﬁll the Nottingham
Health Proﬁle (NHP). Independent variables: age, gender,
educational level, marital status, labour situation. Statis-
tical analysis: descriptive (mean ± SD, absolute and 
relative frequencies) and bivariante analysis (ANOVA).
RESULTS: Age: COPD (66,9 ± 8,9 years); HTA (64,7 ±
10,3); HTA + DM (69,6 ± 9,6). Gender: male 88%; 40%
and 23% (in COPD, HTA and HTA + DM respectively).
Homogenous distribution between educational level,
labour situation retirement and marital status between
groups. NHP: in HTA + DM population and COPD she
is similar, with the exception of the dimensions social 
isolation, (higher score in the COPD) and pain (greater
score in the HTA + DM). Relation between sociodemo-
graphics characteristics and health perceived: the QOL
perceived is worse in the women than in the men (p <
0,05). To greater age, worse physical mobility (p < 0,05);
exists a positive relation between the labour situation
(activity) and physical mobility of patients EPOC and for
all the factors valued by the NHP in the HTA patients.
The educational levels are inﬂuences positively in the 
perception of certain areas of the QOL in HTA (all) 
and HTA + DM (pain, emotional reactions, physical
mobility and total NHP). Married being repels of favor-
able way in concrete aspects of the QOL of patients
COPD (sleep, social isolation and health) and in all those
of the HTA ones patients. CONCLUSION: Any subject
affection of a chronic pathology perceives a health worse
than the general population. The sociodemographics 
features inﬂuence more in those patients than they present
less symptomatic pathologies (HTA), that those that
suffers more symptomatic diseases (COPD or HTA +
DM).
